Zobrazeno 41 - 50
of 83
pro vyhledávání: '"Lee C. Vermeulen"'
Publikováno v:
The quarterly journal of economics. 127(1)
Consumers need information to compare alternatives for markets to function efficiently. Recognizing this, public policies often pair competition with easy access to comparative information. The implicit assumption is that comparison friction--the wed
Autor:
Fred Doloresco, Glen T. Schumock, Edward C. Li, Lee C. Vermeulen, Nilay Shah, Linda M. Matusiak, James M. Hoffman, Robert J. Hunkler
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 69(5)
Purpose Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. Summary Data were analyzed to provide drug expenditure trends for total drug expenditures and the
Autor:
Victor J. Perini, Lee C. Vermeulen
Publikováno v:
American Journal of Health-System Pharmacy. 51:1883-1891
Automated devices for managing medication distribution are described. Shrinking operating budgets are causing many departments of pharmacy to consider automation to maximize the cost-effective use of professional personnel. Many devices and systems t
Autor:
Glen T. Schumock, Linda M. Matusiak, James M. Hoffman, Fred Doloresco, Nilay Shah, Cory E. Fominaya, Lee C. Vermeulen, Robert J. Hunkler
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 68(10)
PURPOSE. Drug expenditure trends in 2009 and 2010, projected drug expenditures for 2011, and factors likely to influence drug expenditures are discussed. SUMMARY. Various factors are likely to influence drug expenditures in 2011, including drugs in d
Autor:
Katsushi Yamada, Elim Lau, Ryuji Ikeda, Kamakshi Sachidanandam, Jill M. Kolesar, Zhisheng Jiang, Lee C. Vermeulen
Publikováno v:
International Journal of Oncology. 38
Gemcitabine is an effective chemotherapy against non-small cell lung cancer (NSCLC). However, resistance to gemcitabine reduces its efficacy. We have isolated gemcitabine-resistant human non-small cell lung cancer A549 cells, termed A549/GR cells. A5
Autor:
Zhisheng Jiang, Shannon M. Kavanaugh, Lee C. Vermeulen, Jill M. Kolesar, Elim Lau, Ryuji Ikeda, Katsushi Yamada
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an effective therapy for non-small cell lung cancer (NSCLC). However, resistance to erlotinib reduces its efficacy. To investigate the basis of erlotinib resistance,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a54d01aee6ca0a021c82413ccd96c4b5
https://europepmc.org/articles/PMC3412472/
https://europepmc.org/articles/PMC3412472/
Publikováno v:
Molecular medicine reports. 3(6)
Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resist
Publikováno v:
JPEN. Journal of parenteral and enteral nutrition. 34(4)
A common problem that complicates use of central venous access devices (CVADs) is occlusion by thrombosis. Alteplase, a recombinant tissue plasminogen activator, is used to restore line patency when thrombosis occurs. Heparin flush is commonly used t
Publikováno v:
Experimental and therapeutic medicine. 1(5)
Vascular endothelial growth factor (VEGF) plays an important role in the process of angiogenesis in many types of cancer, including non-small cell lung cancer (NSCLC), and angiogenesis inhibitors and standard chemotherapy exhibit synergy though an un
Publikováno v:
American Journal of Health-System Pharmacy. 57:1800-1802